7356-11-8

Basic information

• Product Name: 4-Methyl-3-nitrobenzoic acid methyl ester
• Synonyms: METHYL 3-NITRO-4-METHYLBENZOATE;METHYL 4-METHYL-3-NITROBENZOATE;3-NITRO-P-TOLUIC ACID METHYL ESTER;4-METHYL-3-NITROBENZOIC ACID METHYL ESTER;RARECHEM AL BF 0233;4-Methyl-3-Nitro Benzoic Acid Methyl Ester Methyl 4-Methyl-3-Nitro Benzoate;3-NITRO-4-METHYLBENZOICACIDMETHYLESTER;BENZOICACID,4-METHYL-3-NITRO-,METHYLESTER(9CI)
• CAS NO: 7356-11-8
• Molecular Formula: C₉H₉NO₄
• Molecular Weight: 195.17
• EINECS: 230-886-6
• Product Categories: Intermediates of Dyes and Pigments;Aromatic Esters;Organic acids;Benzenes;Building Blocks;C8 to C9;Carbonyl Compounds;Chemical Synthesis;Esters;Organic Building Blocks
• Mol File: 7356-11-8.mol
• Article Data: 14

Chemical Properties

• Melting Point: 49-53°C
• Boiling Point: 298 °C at 760 mmHg
• Flash Point: 110 °C
• Appearance: Similar white crystalline powder
• Density: 1.255 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Soluble in methanol.
• CAS DataBase Reference: 4-Methyl-3-nitrobenzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Methyl-3-nitrobenzoic acid methyl ester(7356-11-8)
• EPA Substance Registry System: 4-Methyl-3-nitrobenzoic acid methyl ester(7356-11-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-43
• Safety Statements: 37/39
• WGK Germany: 2
• TSCA: Yes
• Hazardous Substances Data: 7356-11-8(Hazardous Substances Data)

Usage

Synthesis

Methyl 4-methyl-3-nitrobenzoate is synthesized by the following steps:Acid 33 (100 g, 0.552 mol) was dissolved in MeOH (1000 ml). Conc. ?H2SO4 (30 ml) was added cautiously to this solution. The mixture was ?refluxed for 8 hours. Solvent was distilled off. Ice-cold water was added ?to the residue. It was then extracted with EtOAc, washed with NaHCO3 solution, water, dried (anhydrous Na2SO4), filtered and concentrated in ?vacuo to furnish faint yellow a solid. (91.57 g).

Chemical Properties

White solid

Uses

Methyl 4-methyl-3-nitrobenzoate is used as pharmaceutical intermediate.

InChI:InChI=1/C9H9NO4/c1-6-3-4-7(9(11)14-2)5-8(6)10(12)13/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 939-79-7 4-cyano-2-nitrotoluene 
• 99-75-2 4-methyl-benzoic acid methyl ester 
• 7697-37-2 nitric acid 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 77-78-1 dimethyl sulfate 
• 7647-01-0 hydrogenchloride 
• 159583-78-5 methyl 4-<(phenylthio)methyl>-3-nitrobenzoate 

Downstream Products

• 133831-27-3 methyl 4-(2-(dimethylamino)vinyl)-3-nitrobenzoate 
• 170487-40-8 1H-indazole-6-carboxylic acid methyl ester 
• 1630015-59-6 3-phenyl-5-(6-indazolyl)-1,2,4-oxadiazole 
• 1630015-60-9 3-(3-methylphenyl)-5-(6-indazolyl)-1,2,4-oxadiazole 
• 1630015-61-0 3-(3-fluorophenyl)-5-(6-indazolyl)-1,2,4-oxadiazole 
• 832075-29-3 C₉H₁₂N₂O₂ 
• 81863-45-8 3-(hydroxymethyl)-6-methylaniline 
• 1379359-74-6 5-amino-2-hydroxy-4-methyl-benzoic acid methyl ester 
• 18595-18-1 3-amino-4-methyl benzoic acid methyl ester 
• 219763-69-6 2-((N-acetyl)aminomethyl)-5-((N-acetyl)carbamoyl)-1-nitrobenzene 
• 219763-70-9 2-((N-acetyl)aminomethyl)-5-((N-acetyl)carbamoyl)aniline 
• 134020-58-9 C₈H₉N₃O₃ 

Relevant articles and documents

Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists

The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.

One-pot synthesis of novel 3,5-disubstituted-1,2,4-oxadiazoles from indazole carboxylic acid esters and amidoximes

An efficient and high-yielding one-pot synthesis of 3,5-disubstituted-1,2, 4-oxadiazoles from indazole carboxylic acid methyl esters and amidoximes is described. In this study a series of novel 3,5-disubstituted-1,2,4-oxadiazoles (3a-d), (4a-d), (5a-d), (6a-d), (7a-d) were synthesized using amidoximes 2a-d and indazole carboxylic acid esters (3-6).

PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY

A medicament having an excellent CaSR agonist action which enables the prevention or treatment of diabetes or obesity is provided by a composition comprising the compound represented by general formula (I) as defined, or a salt thereof.